Acarix AB (OSTO:ACARIX) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Acarix AB Debt-to-Asset?

Acarix AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Acarix AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Acarix AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr95.84 Mil. Acarix AB's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Acarix AB Debt-to-Asset Historical Data

The historical data trend for Acarix AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acarix AB Debt-to-Asset Chart

Acarix AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.02

Acarix AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Acarix AB's Debt-to-Asset

For the Medical Devices subindustry, Acarix AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acarix AB's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Acarix AB's Debt-to-Asset falls into.

Acarix AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Acarix AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	62.884
	=	0.00

Acarix AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	95.836
	=	0.00

Acarix AB (OSTO:ACARIX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Acarix AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Acarix AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Acarix AB (OSTO:ACARIX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ACIXF:USA 7AC:Germany

Address

World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19

Website

https://www.acarix.com

Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Acarix AB (OSTO:ACARIX) Headlines

No Headlines